CM313

BIOLOGICAL2 trials

Sponsors

Keymed Biosciences Co.Ltd

Conditions

IgA NephropathyLymphomaMultiple Myeloma

Phase 1

Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma

Keymed Biosciences Co.LtdLymphoma, Multiple Myeloma

Start: 2021-04-26End: 2023-04-30Target: 87Updated: 2021-11-12

Phase 2

Study of CM313 in Subject With IgA Nephropathy

Not yet recruitingNCT06830395

Keymed Biosciences Co.LtdIgA Nephropathy

Start: 2025-09-30End: 2028-08-31Target: 106Updated: 2025-09-19

Related Papers

P925: PHASE 1 TRIAL OF ANTI-CD38 MONOCLONAL ANTIBODY CM313 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA OR LYMPHOMA

HemaSphere2023-08-011 citations